Jeremy Gleeson, MD

home / authors / jeremy-gleeson-md

Articles

November 12th 2021

Cold Agglutinin Disease: Clinical Pearls

Neil Minkoff, MD Jeremy Gleeson, MD Jeremy Lorber, MD Kevin U. Stephens, Sr, JD, MD Mihir Raval, MD, MPH

Take-aways from a discussion on the management of cold agglutinin disease, with expert insight on navigating the healthcare system to optimize patient care.

November 12th 2021

Implications for Using Complement Therapies for Cold Agglutinin Disease

Neil Minkoff, MD Jeremy Lorber, MD Mihir Raval, MD, MPH Kevin U. Stephens, Sr, JD, MD Jeremy Gleeson, MD

Considerations regarding where newer, novel complement therapies will likely fit into the treatment landscape for patients with cold agglutinin disease.

November 12th 2021

Coverage for Complement Therapies for Cold Agglutinin Disease

Neil Minkoff, MD Kevin U. Stephens, Sr, JD, MD Jeremy Gleeson, MD Mihir Raval, MD, MPH

Payers debate criteria for coverage of novel targeted therapies under investigation as use as novel complement therapy for cold agglutinin disease.

November 5th 2021

Cold Agglutinin Disease: Treatment Gaps

Neil Minkoff, MD Kevin U. Stephens, Sr, JD, MD Jeremy Gleeson, MD

Payers react to gaps that impact coverage decisions for therapies available off-label for cold agglutinin disease.

October 29th 2021

Coverage of Anti–B-Cell Therapies for Cold Agglutinin Disease

Neil Minkoff, MD Mihir Raval, MD, MPH Jeremy Lorber, MD Jeremy Gleeson, MD Kevin U. Stephens, Sr, JD, MD

Criteria that support coverage decisions for anti–B-cell therapies for cold agglutinin disease, which are not currently FDA approved.

October 15th 2021

Challenges Managing Cold Agglutinin Disease

Neil Minkoff, MD Jeremy Gleeson, MD Jeremy Lorber, MD Mihir Raval, MD, MPH

A panel of clinicians and payers highlight challenges that impact the treatment of a rare autoimmune hemolytic anemia, cold agglutinin disease.

October 15th 2021

PRO Data & Support for Patients With Cold Agglutinin Disease

Neil Minkoff, MD Kevin U. Stephens, Sr, JD, MD Jeremy Lorber, MD Mihir Raval, MD, MPH Jeremy Gleeson, MD

Payer considerations regarding the measurement of treatment outcomes for patients with cold agglutinin disease, and resources available to help support patients through their care continuum.